SK bioscience Co.,Ltd.

KOSE:A302440 Stock Report

Market Cap: ₩3.5t

SK bioscienceLtd Valuation

Is A302440 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A302440 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A302440's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A302440's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A302440?

Key metric: As A302440 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A302440. This is calculated by dividing A302440's market cap by their current earnings.
What is A302440's PE Ratio?
PE Ratio132.2x
Earnings₩27.43b
Market Cap₩3.51t

Price to Earnings Ratio vs Peers

How does A302440's PE Ratio compare to its peers?

The above table shows the PE ratio for A302440 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average68.8x
A145020 Hugel
26.5x20.7%₩2.9t
A214450 PharmaResearch
23.8x24.6%₩2.2t
A096530 Seegene
44.4x27.2%₩1.0t
A086900 Medy-Tox
180.6x68.1%₩830.0b
A302440 SK bioscienceLtd
128.1x25.1%₩3.5t

Price-To-Earnings vs Peers: A302440 is expensive based on its Price-To-Earnings Ratio (128.1x) compared to the peer average (68.8x).

Price to Earnings Ratio vs Industry

How does A302440's PE Ratio compare vs other companies in the Asian Biotechs Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A302440 132.2xIndustry Avg. 31.5xNo. of Companies11PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A302440 is expensive based on its Price-To-Earnings Ratio (128.1x) compared to the Asian Biotechs industry average (30x).

Price to Earnings Ratio vs Fair Ratio

What is A302440's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A302440 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio132.2x
Fair PE Ratio25.9x

Price-To-Earnings vs Fair Ratio: A302440 is expensive based on its Price-To-Earnings Ratio (128.1x) compared to the estimated Fair Price-To-Earnings Ratio (25.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A302440 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩46,300.00
₩49,333.33
+6.6%
18.4%₩60,000.00₩40,000.00n/a6
Nov ’25₩52,800.00
₩49,333.33
-6.6%
18.4%₩60,000.00₩40,000.00n/a6
Oct ’25₩55,400.00
₩46,800.00
-15.5%
22.5%₩60,000.00₩35,000.00n/a5
Sep ’25₩55,500.00
₩46,800.00
-15.7%
22.5%₩60,000.00₩35,000.00n/a5
Aug ’25₩55,500.00
₩57,000.00
+2.7%
32.0%₩89,000.00₩35,000.00n/a7
Jul ’25₩53,800.00
₩57,714.29
+7.3%
30.6%₩89,000.00₩35,000.00n/a7
Jun ’25₩51,700.00
₩58,000.00
+12.2%
29.9%₩89,000.00₩35,000.00n/a7
May ’25₩58,600.00
₩58,000.00
-1.0%
29.9%₩89,000.00₩35,000.00n/a7
Apr ’25₩61,800.00
₩56,428.57
-8.7%
33.9%₩89,000.00₩31,000.00n/a7
Mar ’25₩61,400.00
₩56,428.57
-8.1%
33.9%₩89,000.00₩31,000.00n/a7
Feb ’25₩64,100.00
₩56,428.57
-12.0%
33.9%₩89,000.00₩31,000.00n/a7
Jan ’25₩72,000.00
₩58,625.00
-18.6%
31.2%₩89,000.00₩33,000.00n/a8
Dec ’24₩67,800.00
₩58,625.00
-13.5%
31.2%₩89,000.00₩33,000.00n/a8
Nov ’24₩60,700.00
₩58,625.00
-3.4%
31.2%₩89,000.00₩33,000.00₩52,800.008
Oct ’24₩67,700.00
₩62,857.14
-7.2%
31.1%₩98,000.00₩35,000.00₩55,400.007
Sep ’24₩72,100.00
₩61,250.00
-15.0%
30.7%₩98,000.00₩35,000.00₩55,500.008
Aug ’24₩77,400.00
₩61,250.00
-20.9%
30.7%₩98,000.00₩35,000.00₩55,500.008
Jul ’24₩79,500.00
₩61,625.00
-22.5%
27.1%₩98,000.00₩45,000.00₩53,800.008
Jun ’24₩81,600.00
₩63,444.44
-22.2%
25.9%₩90,000.00₩45,000.00₩51,700.009
May ’24₩70,400.00
₩63,666.67
-9.6%
24.5%₩90,000.00₩48,000.00₩58,600.009
Apr ’24₩72,100.00
₩66,666.67
-7.5%
20.5%₩90,000.00₩49,000.00₩61,800.009
Mar ’24₩69,700.00
₩67,100.00
-3.7%
19.4%₩90,000.00₩49,000.00₩61,400.0010
Feb ’24₩77,000.00
₩86,727.27
+12.6%
44.5%₩170,000.00₩50,000.00₩64,100.0011
Jan ’24₩73,500.00
₩90,090.91
+22.6%
41.1%₩170,000.00₩50,000.00₩72,000.0011
Dec ’23₩83,200.00
₩90,363.64
+8.6%
40.8%₩170,000.00₩50,000.00₩67,800.0011
Nov ’23₩76,300.00
₩105,545.45
+38.3%
47.3%₩200,000.00₩50,000.00₩60,700.0011

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Hugel

₩2.9t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩268,500.00

7D

-4.4%

1Y

79.2%

J2KBIO

₩54.2b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,490.00

7D

-13.3%

1Y

n/a

Medy-Tox

₩830.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩123,300.00

7D

-10.8%

1Y

-41.6%